140 filings
Page 7 of 7
8-K
1mlzukn200egjcf9
2 Dec 14
Entry into a Material Definitive Agreement
12:00am
8-K
p0177otp4387cz4e7bs
18 Nov 14
Arch Therapeutics Reports Positive Preclinical Data from Study of AC5
12:00am
8-K
iae2b0c22a262
6 Nov 14
Other Events
12:00am
8-K
xe00dldr90hwk5 65n
8 Sep 14
Arch Therapeutics Announces Positive Preclinical Data from an Independent Study of AC5 Surgical Hemostatic Device™ in Animals on Blood Thinners
12:00am
8-K
62orfb
25 Aug 14
Arch Therapeutics Announces Positive Preclinical Data from its Study of AC5 Surgical Hemostatic Device™ in Animals on Blood Thinner
12:00am
8-K
ljl0g45 6fw5ljts87v0
6 Aug 14
Arch Therapeutics Announces Third Quarter 2014 Results
12:00am
8-K
qopql mweodw
7 Jul 14
Arch Therapeutics Appoints Richard Davis as Chief Financial Officer
12:00am
8-K
ddqaiyf7g3lgk18kqm
1 May 14
Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
12:00am
8-K
isvjcc9p90zt1m9
27 Mar 14
Departure of Directors or Certain Officers
12:00am
8-K
lpf9jh6c fxsdbgwvg
10 Feb 14
Entry into a Material Definitive Agreement
12:00am
8-K
qtnb6rhg2zuoq9qcvrv
31 Jan 14
Arch Therapeutics Announces $2.85 Million Private Placement
12:00am
8-K
p9xgadh21w8zyldhc
4 Oct 13
Entry into a Material Definitive Agreement
12:00am
8-K
dc1 xyxn334v2f9d
8 Jul 13
Arch Therapeutics Appoints Senior Management Team Members
12:00am
8-K
sh0c ywnmkoz
26 Jun 13
Report of Independent Registered Public Accounting Firm
12:00am
8-K
p7dc8 t9yn
24 Jun 13
Departure of Directors or Certain Officers
12:00am
8-K
2grsto2
5 Jun 13
Amendments to Articles of Incorporation or Bylaws
12:00am
8-K
16z 12agw
24 May 13
Other Events
12:00am
8-K
6hh dskszwlb7fxw
13 May 13
Entry into a Material Definitive Agreement
12:00am
8-K
wxr8n
29 Apr 13
Amendments to Articles of Incorporation or Bylaws
12:00am
8-K
q7il4el9q00j32b
25 Apr 13
Entry into a Material Definitive Agreement
12:00am